359 related articles for article (PubMed ID: 18309957)
1. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Boeck S; Heinemann V
J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
[No Abstract] [Full Text] [Related]
2. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
Boeck S; Heinemann V
Future Oncol; 2008 Feb; 4(1):41-50. PubMed ID: 18240999
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
4. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Kourie HR; Gharios J; Kattan J
Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
[No Abstract] [Full Text] [Related]
5. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
6. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
7. [Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].
Lee JL; Kim YT
Korean J Gastroenterol; 2008 Jul; 52(1):59-63. PubMed ID: 19077495
[No Abstract] [Full Text] [Related]
8. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Ryu JK
Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697
[TBL] [Abstract][Full Text] [Related]
9. [Gemcitabine and pancreatic cancer].
Prost P; Ychou M; Azria D
Bull Cancer; 2002 Aug; 89 Spec No():S91-5. PubMed ID: 12449037
[TBL] [Abstract][Full Text] [Related]
10. Achieving the best of both worlds.
Ko AH; Cella D
J Clin Oncol; 2013 Jan; 31(1):3-4. PubMed ID: 23213099
[No Abstract] [Full Text] [Related]
11. [How I treat ... An advanced pancreatic cancer].
Polus M; Jerusalem G; Sautois B; Silvestre RM; Fillet G
Rev Med Liege; 2002 Mar; 57(3):131-4. PubMed ID: 12014258
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Kozuch P; Petryk M; Evans A; Bruckner HW
Surg Clin North Am; 2001 Jun; 81(3):683-90. PubMed ID: 11459281
[TBL] [Abstract][Full Text] [Related]
13. [Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Brunet R; Fonck M
Rev Med Interne; 1999 Sep; 20(9):816-20. PubMed ID: 10522306
[TBL] [Abstract][Full Text] [Related]
14. First line therapy for metastatic pancreatic cancer.
Jarboe J; Saif MW
JOP; 2013 Jul; 14(4):340-3. PubMed ID: 23846923
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic pancreatic cancer.
Ko AH; Tempero MA
J Natl Compr Canc Netw; 2005 Sep; 3(5):627-36. PubMed ID: 16194454
[TBL] [Abstract][Full Text] [Related]
16. Current and future strategies for treating metastatic pancreatic cancer.
Berlin JD
Clin Adv Hematol Oncol; 2004 Aug; 2(8):510-2. PubMed ID: 16163230
[No Abstract] [Full Text] [Related]
17. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
18. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
19. [Gemzar (gemcitabine)--a new chemotherapeutic agent for pancreatic cancer].
Merimsky O; Chaitchik S
Harefuah; 1997 Sep; 133(5-6):208-12. PubMed ID: 9461693
[No Abstract] [Full Text] [Related]
20. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
Banu E; Banu A; Fodor A; Landi B; Rougier P; Chatellier G; Andrieu JM; Oudard S
Drugs Aging; 2007; 24(10):865-79. PubMed ID: 17896834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]